Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19520407 | 0.91 | SMN1; SMN2 (0.63) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19520410 | 0.91 | TSHR (0.64) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19520380 | 0.88 | TSHR (0.63) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19520379 | 0.88 | TSHR (0.76) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL24021623 | 0.86 | TSHR (0.60) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19520575 | 0.85 | SMN1; SMN2 (0.57) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19538781 | 0.84 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19520585 | 0.82 | ALDH1A1 (0.68) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19520409 | 0.81 | SMN1; SMN2 (0.54) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19538759 | 0.80 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448853-B1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2021-11-17 | — | — | EP | claimed |
| US-10730865-B2 | Compounds for modulating aquaporins | APOGLYX AB (SE) | 2020-08-04 | — | — | US | claimed |
| US-20190127360-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2019-05-02 | — | — | US | claimed |
| WO-2017186893-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2017-11-02 | — | — | WO | claimed |
| US-10730865-B2 | Compounds for modulating aquaporins | APOGLYX AB (SE) | 2020-08-04 | — | — | US | disclosed |
| US-10730865-B2 | Compounds for modulating aquaporins | APOGLYX AB (SE) | 2020-08-04 | — | — | US | disclosed |
| US-20190127360-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2019-05-02 | — | — | US | disclosed |
| US-20190127360-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2019-05-02 | — | — | US | disclosed |
| WO-2017186893-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017186893-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2017-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730865-B2 | Compounds for modulating aquaporins | AQP1, AQP4, AQP3 | TSHR 3510/4885SMN1; SMN2 4791/4885ALDH1A1 1917/4885 |
| US-20190127360-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | AQP1, AQP4, AQP3 | TSHR 3510/4885SMN1; SMN2 4791/4885ALDH1A1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.